Is Bluejay Diagnostics Inc (BJDX) overvalued? · rev $249.0K
Bluejay Diagnostics Inc (BJDX) is a medical devices company listed on US.
This page asks whether Bluejay Diagnostics Inc (BJDX) looks expensive on cached numbers — not a short thesis.
Latest reported BJDX revenue for 2022-12-31 was $249.0K. Net income was -$9.3M. BJDX currently screens at market cap $5.0M.
BJDX currently screens at market cap $5.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BJDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BJDX stock page for the full model, not this heading.
Not investment advice.